100
Participants
Start Date
April 2, 2022
Primary Completion Date
September 19, 2028
Study Completion Date
September 19, 2028
Pembrolizumab
Intravenous (IV) infusion
Oxaliplatin
85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
Leucovorin
400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
5-fluorouracil
400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
Irinotecan
180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
Bevacizumab
IV infusion
Cetuximab
IV infusion
RECRUITING
Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing
COMPLETED
Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011), Beijing
COMPLETED
The first affiliated hospital of China medical university ( Site 0043), Shemyang
RECRUITING
Harbin Medical University Cancer Hospital ( Site 0007), Harbin
RECRUITING
Fudan University Shanghai Cancer Center-Oncology ( Site 0046), Shanghai
RECRUITING
Shanghai East Hospital ( Site 0022), Shanghai
COMPLETED
Shanghai Changhai Hospital ( Site 0024), Shanghai
RECRUITING
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 0002), Nanjing
RECRUITING
The Affiliated Jiangyin Hospital of Southeast University Medical College ( Site 0037), Jiangyin
COMPLETED
Jinan Central Hospital-oncology department ( Site 0021), Jinan
RECRUITING
Shandong Cancer Hospital ( Site 0041), Jinan
RECRUITING
Zhejiang Cancer Hospital-oncology-abdominal neoplasms ( Site 0028), Hangzhou
RECRUITING
Fujian Provincial Cancer Hospital ( Site 0009), Fuzhou
RECRUITING
The First Affiliated Hospital of Chongqing Medical University ( Site 0051), Chongqing
RECRUITING
Chongqing University Cancer Hospital-Medical Oncology ( Site 0012), Chongqing
RECRUITING
The Third Xiangya Hospital of Central South University ( Site 0031), Changsha
COMPLETED
Tongji Hospital Tongji Medical,Science & Technology-oncology ( Site 0018), Wuhan
RECRUITING
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 0008), Wuhan
RECRUITING
Henan Cancer Hospital-henan cancer hospital ( Site 0015), Zhengzhou
RECRUITING
Sun Yat-sen University Cancer Center ( Site 0047), Guangzhou
RECRUITING
Guangdong Provincial People's Hospital ( Site 0035), Guangzhou
RECRUITING
The First Affiliated Hospital, Sun Yat-sen University ( Site 0014), Guangzhou
RECRUITING
The Sixth Affiliated Hospital of Sun Yat-sen University-Oncology ( Site 0048), Guangzhou
COMPLETED
Cancer Hospital of Shantou University Medical College ( Site 0036), Shantou
RECRUITING
Guangxi Medical University Affiliated Tumor Hospital ( Site 0039), Nanning
RECRUITING
Sichuan Cancer Hospital. ( Site 0050), Chengdu
RECRUITING
West China Hospital, Sichuan University ( Site 0044), Chengdu
RECRUITING
Yunnan Province Cancer Hospital-Colorectal surgery ( Site 0006), Kunming
RECRUITING
Tangdu Hospital of Fourth Military Medical University of Chi-General Surgery ( Site 0045), Xi'an
RECRUITING
The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 0049), Ürümqi
RECRUITING
Shanxi Cancer Hospital ( Site 0032), Taiyuan
COMPLETED
Tianjin Medical University Cancer Institute and Hospital-Gastric oncology ( Site 0019), Tianjin
Merck Sharp & Dohme LLC
INDUSTRY